Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Scholar Rock Holding Corp

NASDAQ: SRRK · Life Sciences · 5 alerts · CIK 1727196

Share price
$44.54Close, Nov 16
Market cap
$5.43B
Shares outstanding
122MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Scholar Rock Holding Corp filings on SEC EDGAR ↗

8:31 AM ET 8-K
Regulatory Approval

Scholar Rock Holding Regulatory Approval

Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older. The filing also clarifies that the approval includes a post-marketing requirement for a pregnancy safety study and a request for alert reports regarding bone fractures.

8:01 AM ET 8-K
Regulatory Approval

Scholar Rock Holding Regulatory Approval

Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children aged 2 and older. This marks the first and only muscle-targeted treatment approved for SMA, representing a significant therapeutic breakthrough for the company's myostatin biology platform.

Earnings call
Sep 14, 2026, 8:00 AM ET

“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.”

David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.